Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization
8.6.2026 15:00:00 CEST | Business Wire | Press release
Ulf Wiinberg appointed to Board of DirectorsWilliam “Bill” MacKenzie hired as Senior Vice President – Finance
Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance.
Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy.
Mr. Wiinberg’s experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth’s Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acquired by Pfizer.
Ulf serves as a director on several company boards including UCB, a global biopharmaceutical company headquartered in Brussels, Belgium, Alfa Laval AB, Lund, Sweden, SIGRID Therapeutics AB, Stockholm Sweden and MiNK Therapeutics, Inc., Lexington, MA.
Commenting on his appointment, Mr. Wiinberg said, “I look forward to working collaboratively with my fellow directors and the management team at this exciting time in Neuraptive’s journey as the company continues to advance its important work to address the unmet needs of physicians and patients impacted by peripheral nerve injuries.”
Bill MacKenzie, Senior Vice President-Finance, will lead the enterprise finance function and the development of the company's operational infrastructure. Since March 2025, Bill served as consultant, Head of Finance at Neuraptive. He brings over a decade of biotech financial leadership, progressing from senior accountant to executive roles including Head of Accounting and Head of FP&A for revenue, commercial, and R&D. Bill's career includes positions at Sage Therapeutics from 2022 to 2024, Prelude Therapeutics from 2021 to 2022, LifeScan from 2020 to 2021, Zyla Life Sciences from 2015 to 2020, spanning public, private, and PE-backed environments. Bill’s background includes multiple FDA-approved products and navigating complex corporate restructurings.
“We are thrilled to welcome Bill and Ulf to the company,” said Bob Radie, Chairman of the Board and Chief Executive Officer of Neuraptive. “Bill’s deep financial expertise and leadership will be instrumental as we continue to progress NTX-001 toward commercialization, while Ulf’s global industry experience and strategic insight will provide immense value to our Board and leadership team. “
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company’s headquarters are in Chesterbrook, PA. For more information, see www.neuraptive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608270654/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
Resident Evil Veronica to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Capcom aims to further enhance the IP’s value by remaking a popular title of the series – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Veronica, the latest title in the Resident Evil series, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608994346/en/ Resident Evil Veronica key art The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to survive terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 201 million* units. Resident Evil Veronica is a remake of the original Resident Evil Code: Veronica, released in the year 2000. While preserving the appeal of the original, Capcom is developing the 2027 release as the latest installment of the Resident Evil series, with a reimagined story and high-quality g
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 14:00:00 CEST | Press release
Agreement to design, build and operate advanced water solution Project to advance integrated water reuse capability, significantly reducing freshwater demand Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the str
Seequent and Cascade Institute Partner to Map Canada’s Deep Geothermal Resources8.6.2026 14:00:00 CEST | Press release
State-of-the-art thermal model will provide a nationwide view of subsurface heat to accelerate Canada’s clean energy goals Seequent, The Bentley Subsurface Company, and the Cascade Institute today announced a collaboration to develop a Canadian Thermal Model. This landmark national initiative will reveal Canada’s deep geothermal resources and accelerate the development of renewable energy. The announcement comes on the opening day of the world’s biggest geothermal event, the World Geothermal Congress, being held in Calgary from 8 to 11 June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608741816/en/ The Canadian Thermal Model will integrate over 20 input layers of geoscientific data related to geothermal energy to evaluate Canada’s nationwide deep heat resources. As investment in geothermal energy surges globally as a reliable, always-on clean power source, the Canadian Thermal Model will create a comprehensive national
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform8.6.2026 14:00:00 CEST | Press release
Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief Scientific Officer, further building AdvanCell’s U.S. based leadership team Simon Puttick, PhD, transitions to Chief Isotope Development Officer and continues to lead isotope innovation efforts from Australia Appointments reflect AdvanCell’s continued investment in pipeline advancement, global scale-up, manufacturing readiness and isotope capabilities AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Justyna Kelly as Chief Technology Officer (CTO) and François Gaudet as Chief Scientific Officer (CSO), expanding the company’s executive leadership team in the U.S. as it continues to scale its U.S. capabilities, and advance its growing pipeline of innovative targeted alpha therapies. Justyna Kelly will lead AdvanCell’s global technical operations strategy, including CMC, GMP production and clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom